Cyclooxygenase (COX-1/COX-2) plus histamine H2 receptor

Class

Fixed-dose combination: NSAID (ibuprofen) + H2-receptor antagonist (famotidine) for GI-protective co-therapy

Pathway

Ibuprofen inhibits COX-mediated prostaglandin synthesis for anti-inflammatory/analgesic effect; famotidine reduces gastric acid to mitigate NSAID-induced GI injury

Cyclooxygenase (COX) exists as two isoforms, COX-1 and COX-2, both of which convert arachidonic acid into prostaglandins, lipid mediators that promote inflammation, pain, and fever, but also serve protective roles such as maintaining the mucous lining of the stomach. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen block both isoforms, reducing prostaglandin-driven inflammation and pain, but this same inhibition removes protective prostaglandin signaling in the stomach lining, increasing the risk of ulcers and gastrointestinal bleeding, particularly with prolonged use. Histamine H2 receptors sit on gastric parietal cells and, when activated by histamine, drive acid secretion. Blocking these receptors with an H2-receptor antagonist such as famotidine reduces gastric acid output, lowering the acidity that would otherwise worsen NSAID-related mucosal injury. Combining an NSAID with an H2-receptor antagonist in a single fixed-dose product addresses the anti-inflammatory need and its principal safety liability together, aiming to preserve analgesic and anti-inflammatory efficacy while reducing upper gastrointestinal risk. This dual mechanism is broadly relevant wherever chronic or frequent NSAID use is needed, such as in musculoskeletal pain and inflammatory conditions, where gastrointestinal tolerability often limits how a drug can be used over time.